Download Report PDF Instantly
The global Spinal Cord Stimulation (SCS) Devices market was valued at 2168.43 Million USD in 2021 and will grow with a CAGR of 6.44% from 2021 to 2027, based on newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
A Spinal Cord Stimulator (SCS) or Dorsal Column Stimulator (DCS) is a type of implantable neuromodulation device (sometimes called a "pain pacemaker") that is used to send electrical signals to select areas of the spinal cord (dorsal columns) for the treatment of certain pain conditions. SCS is a consideration for people who have a pain condition that has not responded to more conservative therapy.The classification of spinal cord stimulation devices includes rechargeable type and non-rechargeable type. The proportion of rechargeable type in 2019 is about 69%, and the proportion is in increasing trend from 2015 to 2019. Spinal cord stimulation devices are widely used in Hospitals and Ambulatory Surgery Centers. The most proportion of spinal cord stimulation devices is used in Hospitals, and the proportion in 2019 is 71%. North America is the largest consumption place, with a consumption market share nearly 57.7% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 24%. Market competition is intense. Medtronic, Boston Scientific, Abbott (St. Jude Medical), Nevro, Nuvectra are the leaders of the industry. And top 3 account for around 79% of the total market share. These existing companies are making investments in several research activities to launch new devices.
By Market Verdors:
Key Indicators Analysed
Key Reasons to Purchase